That is how ASCRS President Elizabeth Yeu, MD describes her surgical experience with MICOR 700, an advanced technology that changes how a lens is removed from the eye during cataract surgery.  

In the first-ever presentation of this device at the recent ASCRS meeting in San Diego, Dr. Yeu commented on the advantages of MICOR 700 compared with phaco emulsification: 

·     Single-use disposable handheld device for lens extraction

·     Improved surgeon control by eliminating the foot pedal

·     Innovative design to reduce risk of bag rupture and iris tear

·     Hand-sized footprint and less waste of materials

Equally important, Dr. Yeu emphasized how much better this technology is for her surgical team, reducing turnaround time as well as eliminating many of the steps required in performing traditional cataract surgery with phaco. 

Surgeons who have already used this technology believe it sets a new standard for efficiency, safety and sustainability. Here are comments by several surgeons along with seeing MICOR 700 in use: Click here or the image below to watch.

MICOR 700 was developed in the United States under a stealth R&D program by the cataract technology division of Zeiss. This same team developed and launched the miLOOP device in 2017, and their company (ianTECH) was acquired by Zeiss the following year.  Having gone through extensive clinical trials, MICOR 700 is now FDA cleared and available for sale.  

We are reaching out to you and other leading surgeons who are likely going to be most interested in this technology. Our plan is to prioritize practices who want to be among the first to provide this premium technology for their patients and are willing to make case volume commitments. 

If you would like to become a MICOR customer in 2023-2024, please click below and provide information about your practice and one of our clinical sales specialists will contact you directly. 

Sincerely,

Jim Simms

Head, Sales and Marketing

Carl Zeiss Meditec Cataract Technology